Translate
About
Mabwell (shanghai) Bioscience Co. Ltd. A (SHG:688062) — investor relations, events, news, and company updates on 6ix.
Latest News
Jan 22 2026
Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.
Dec 31 2025
Mabwell's Adalimumab Biosimilar Receives Marketing Approval in Indonesia
Dec 30 2025
Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring
Dec 24 2025
Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study
Dec 16 2025
Mabwell Announces First Overseas Commercial Shipment of Denosumab Injection